'I Dealt With Gangsters, Shakedowns, Loan Sharks And Government Corruption,' Says Entrepreneur Who Built The First Cannabis Unicorn

Zinger Key Points
  • Adam Bierman, the mastermind behind MedMen Enterprises Inc, tells all in a new book, which will be made into a 3-part series.
  • Bierman, who took MedMen public in 2018 and watched as it soar to a remarkable $2 billion valuation, is keen to tell the world his story.
  • Once hailed as the first cannabis unicorn, MedMen filed for bankruptcy in April 2024 with at least $411 million in liabilities.

Get ready to dive into the world of cannabis entrepreneurship as Bungalow Media + Entertainment along with writer and producer Zach Goldbaum undertake a three-part series about Adam Bierman, the mastermind behind MedMen Enterprises Inc, the first American cannabis unicorn.

The series is based on Bierman’s upcoming tell-all book, “Weed Empire: How I Battled Gangsters, Investment Banks, and the Department of Justice to Build the Cannabis Industry in America," scheduled to be released in April 2025.

“It’s an amazing origin story about one man’s fight against the establishment," said Robert Friedman, CEO of Bungalow Media + Entertainment. "Adam takes us on an amazing, tell-all journey of the new Wild West of hubris and greed while navigating a treacherous world, hoping to attract suburban moms, dads, and stoners alike.”

Together with Andrew Modlin, Bierman founded MedMen in 2010. What started out as a single store in California, "skyrocketed off the technical graphs, becoming the first mainstream cannabis company in the world to hit every screen in America.," as reported Benzinga's Nicolás Jose Rodriguez earlier.

Read Also: Adam Bierman, Co-founder Of American’s First Cannabis Unicorn, Teams Up with Female-led Bombatta Seeking To Transform The Marijuana Landscape

  • Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

Bierman took MedMen public in 2018, quickly propelling the company to a remarkable $2 billion valuation. However, after the company's 2018 bid to acquire PharmaCann in a $682 million all-stock deal was not fulfilled, Bierman parted ways with MedMen in 2020.

After years of legal hurdles, Bierman won a $3.1 million arbitration settlement from MedMen in 2023.

"We were the first cannabis unicorn, the first billion-dollar valuation in history in the US, first private equity fund to raise money to deploy into plant-touching businesses, I think we were the first nationally union-friendly cannabis business, raised a lot of money, bought a lot of assets, built a lot of stores, pissed a lot of people off, made a lot of mistakes, learned a lot of lessons, and along the way had that ‘north star' of making the world a better place through access to legal regulated cannabis. We were doing things for the first time (…) and inevitably means you are pissing people off," Bierman told Javier Hasse and Elliot Lane during a 2022 Benzinga Cannabis Insider episode.

Now, the former MedMen CEO says he wants to tell the world "what it took to bring weed to Main Street America.”

“Living at the intersection of criminality, politics, finance and pop culture; I dealt with gangsters, shakedowns, loan sharks and government corruption at the highest level," Bierman said in a press release on Thursday. "It’s a dynamic story and the Bungalow team’s commitment to sharing the account with the world has been invigorating.”

Read Next:

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisEntertainmentNewsEntrepreneurshipTop StoriesMediaAdam BiermanAndrew ModlinBungalow Media + Entertainmentcannabis documentaryMedMenRobert FriedmanZach Goldbaum
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.